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ABSTRACT
The Hippo pathway regulates organ size, growth and comprises several tumor 
related factors, including the oncoprotein YAP1 and the tumor suppressor RASSF1A. 
RASSF1A is frequently epigenetically inactivated in cancer. In our study, we analyzed 
the effect of RASSF1A on the function of YAP1. Expression of YAP1 resulted in 
the downregulation of several tumor suppressor genes and induction of S-phase. 
Co-expression with RASSF1A normalized the expression levels of these tumor 
suppressors and induced a G0-G1 arrest and apoptosis. This effect was associated 
with the reduction of MDM2 and the increase of p53. These data suggest that the 
tumor suppressor RASSF1A inhibits the oncogenic potential of YAP1. Additionally, we 
could show that ANKRD1 is a YAP1 target gene that is induced by RASSF1A. Further 
analysis revealed that ANKRD1 is epigenetically inactivated in human cancer. ANKRD1 
expression induced the expression of TP53 as well as BAX and CDKN1A and reduced 
colony formation of cancer cells. We found that ANKRD1 interacts with p53 and is 
involved in the destabilization of MDM2. Additionally, our data indicate that the tumor-
suppressive effect of ANKRD1 depends on the presence of p53. These results suggest 
that ANKRD1 is a tumor-suppressive downstream target of the Hippo pathway that 
is epigenetically silenced in human cancer.
INTRODUCTION
The Hippo pathway is a kinase cascade that 
regulates the organ size and plays an important role in 
cell differentiation, proliferation and cell death [1]. In 
this pathway, the tumor suppressor RASSF1A activates 
the mammalian STE20 like kinases 1 and 2 (MST1/
MST2) via its Salvador/RASSF/Hippo domain [2, 3]. 
The hippo kinases MST1/MST2 in turn phosphorylate the 
large tumor suppressor kinases LATS1 and LATS2 [4]. 
Activated LATS1/LATS2 kinases phosphorylate the 
transcriptional regulator YAP1 in a HXRXXS context 
in S61, S109, S127, S164 and S381 [5–7]. Depending 
on the cellular context, YAP1 acts as a co-activator 
of transcription factors such as TEAD [8], SMAD [9] 
or TP73 [10] to regulate the expression of target genes 
that are involved in cell proliferation or apoptosis. 
YAP1 can be also phosphorylated by c-Abl on Y357 
in response to DNA damage, thereby increasing the 
affinity of YAP1 to TP73 [11]. It was also reported 
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that phosphorylated YAP1 interacts with 14-3-3 and is 
released into in the cytoplasm [12]. Phosphorylation of 
YAP1 has been correlated with its poly-ubiquitination and 
degradation [13]. It has been described that YAP1 per se 
rather acts as an oncogene and induces proliferation [8]. 
Furthermore, tumor tissues display an elevated YAP1 
expression compared to normal tissues due to the 
amplification of the YAP gene locus [14, 15]. In lung 
cancer, YAP1 overexpression has been correlated with a 
poor prognosis [16]. YAP1 target genes, which promote its 
growth inducing function, are CTGF [8] or cyclin D1 [17]. 
Previous reports have suggested that the tumor suppressive 
potential of YAP1 is due to its binding to TP73 [5, 10] 
and its regulation by RASSF1A leading to the expression 
of pro-apoptotic genes like BBC3/PUMA and BAX 
[5, 11]. The transcriptional regulator Ankyrin repeat 
domain 1 (ANKRD1) has been characterized as a further 
YAP1 target gene [18, 19]. It has been demonstrated that 
Ankrd1 acts as a co-activator of p53 [20] and plays a role 
in apoptosis by inducing the expression of Bax in mice 
cardiomyocytes [21]. p53 regulates the expression of 
RASSF1A and MDM2 by positive and negative feedback 
loops [22–28]. Thus, the tumor-related functions of 
YAP1 may depend on different upstream activators and/
or transcriptional co-factors resulting in the activation of 
distinct target genes [1, 5, 29, 30].
The scaffold protein RASSF1A is a versatile tumor 
suppressor that regulates microtubule stability, cell cycle 
progression and apoptosis [31]. RASSF1A induces 
apoptosis through the Hippo pathway by regulating the 
MST1/MST2 activation [3, 5, 32, 33]. According to 
several studies, RASSF1A is frequently epigenetically 
inactivated in several types of cancer including lung 
[34], skin cancer [35], prostate [36] and hepatocellular 
carcinoma [37]. Thus, RASSF1A silencing via its promoter 
hypermethylation may contribute to the oncogenic 
deregulation of YAP1.
To study the effect of RASSF1A on the 
transcriptional function of YAP1, we generated a YAP1 
inducible cell system. Hereby, we demonstrated that 
RASSF1A co-regulates the expression of YAP1 target 
genes, including ANKRD1. Further analysis showed that 
ANKRD1 acts by destabilizing MDM2 and inducing 
p53 and BAX. Additional data suggest ANKRD1 is 
epigenetically inactivated in cancer cells and its tumor 
suppressor role depends on p53.
RESULTS
YAP1 regulates the expression of tumor 
suppressor genes
In order to investigate the effect of YAP1 on the 
expression of tumor suppressor genes, we generated an 
inducible Tet-On System in HEK293 cells (TREx293). 
These cells express low level of endogenous YAP1 and 
therefore we stably transfected YAP1 (Figure 1). This 
system allows an induction of YAP1 with doxycycline 
(Dox). Dox-treatment of the YAP1 inducible cells 
resulted in a 12-fold increase of the YAP1 mRNA level 
compared to the control cells (Figure 1A) and the 
induction was confirmed on protein level (Figure 1C). 
Subsequently, we analyzed the expression of YAP1 target 
genes (ANKRD1, CTGF, BAX, CDKN1A and BBC3) by 
qRT-PCR. YAP1 significantly induced the expression of 
ANKRD1 (3.3-fold) and CTGF (2.3-fold) (Figure 1B). 
Interestingly, a significant decrease in the expression 
of BAX (24%), CDKN1A (33%) and BBC3 (27%) was 
detected (Figure 1B). Moreover, YAP1 induction also 
resulted in significantly lower RASSF1A (48%) and 
TP53 (29%) expression levels compared to untreated 
cells (Figure 1B). In contrast, the expression of YAP1 
target genes was unaffected in Dox-treated TREx293 
control cells (Supplementary Figure 1). Additionally, we 
also analyzed 12 individual YAP1 inducible TREx293 
clones, which exhibited different YAP1 levels upon 
Dox-treatment (Supplementary Figure 2) and analyzed 
the mRNA level of ANKRD1, CTGF, BAX, CDKN1A 
and BBC3. In these clones the YAP1 level significantly 
correlated with ANKRD1, CTGF, BAX and BBC3 
expression (Supplementary Figure 3). For CDKN1A, 
a considerable trend toward significance was observed 
(Supplementary Figure 3). The suppressive effect of YAP1 
was validated by luciferase promoter assays for CDKN1A 
(18%; p < 0.0001), BAX (7%; p = 0.02) and for a synthetic 
promoter with 13 conserved TP53 binding sites (28%; 
p < 0.001; Figure 3B).
RASSF1A neutralizes the oncogenic potential of 
YAP1
The tumor suppressor RASSF1A plays an 
important role in the regulation of the Hippo pathway 
and is frequently hypermethylated in different human 
cancers [31]. We analyzed the methylation levels of core 
Hippo components such as KIBRA, RASSF1A, MST1, 
MST2, WW45, LATS1, LATS2 and YAP1 in five matched 
primary tumors (hepatocellular carcinoma) and normal 
liver samples by combined bisulfite restriction analysis 
(Supplementary Figure 4). RASSF1A was the only gene 
that exhibited a tumor-specific methylation pattern in 
these samples. YAP1 was unmethylated in the tumor as 
well as the normal samples (Supplementary Figure 4). 
In the TREx293 cells, the promoter of RASSF1A is 
hypermethylated (Supplementary Figure 5). To analyze 
the effect of RASSF1A re-expression on YAP1 function, 
we transfected the YAP1 inducible TREx293 cells with 
GFP-RASSF1A or GFP (Figure 1C) and analyzed the 
cell cycle distribution via flow cytometry (Figure 2A). 
Doxycycline-dependent overexpression of YAP1 resulted 
in a significant reduction of the cell count in the G0/G1 
phase and an increased number of cells in the S-phase 
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(p < 0.001) compared to the untreated cells (Figure 2A). 
In contrast, the expression of RASSF1A counteracts 
the induction of the S-phase by YAP1 and arrests the 
TREx293 cells in G0/G1 phase (p < 0.001). Additionally 
via fluorescence microscopy, we observed that upon 
RASSF1A transfection, an increased number of apoptotic 
cells (fragmented and deformed nuclei) were detected 
(Figure 2B). Interestingly in HEK293T cells, the co-
expression of RASSF1A and YAP1 significantly increased 
the expression of ANKRD1 in comparison to the control 
and YAP1 by itself (p = 0.007 and p = 0.04 respectively; 
Figure 2C). In HeLa cells that express endogenous 
RASSF1A [34], ANKRD1 induction by RASSF1A and 
YAP1 co-transfection was absent (Figure 2D). However 
for CTGF expression, RASSF1A co-expression had no 
additional effect compared to YAP1 alone (Figure 3A).
For the identification of novel RASSF1A-
regulated YAP1 target genes, we performed a genome-
wide expression analysis with the help of microarrays 
(Table 1). Hereby, we used RNA from 106-sorted cells 
with GFP or GFP-RASSF1A and with or without YAP1 
induction (Supplementary Figure 6). The Dox-dependent 
induction of YAP1 was confirmed on RNA and protein 
level (Supplementary Figure 6). We also verified that 
the YAP1 induction reduced the expression of RASSF1A 
by 50% (Figure 1B, Supplementary Figure 6D). Table 1 
shows the expression levels of ANKRD1, TP53, BAX 
and CDKN1A by means of the microarray. Hereby, we 
confirmed the YAP1 and RASSF1A-induced upregulation 
of ANKRD1 (3.4-fold). Furthermore, the downregulation 
of TP53 (0.79-fold), BAX (0.63-fold) and CDKN1A 
(0.63-fold) through the induction of YAP1 were verified 
(Table 1). Interestingly, we observed that the re-expression 
of RASSF1A counteracted the YAP1 induced reduction of 
TP53, BAX and CDNK1A on RNA level in TREx293 cells 
(Table 1). These results were further validated by qRT-
PCR (Figure 3A). Co-expression of RASSF1A and YAP1 
significantly induced the expression of ANKRD1, TP53, 
BAX and CDKN1A compared to YAP1 only (Figure 3A). 
For MDM2 mRNA level, RASSF1A and YAP1 co-
expression significantly reduced the expression compared 
to YAP1 (Figure 3A). We further analyzed the effect of 
RASSF1A with the help of promoter assays (Figure 3B). 
RASSF1A significantly counteracted the YAP1 induced 
repression of synthetic TP53 target, CDKN1A and BAX 
promoters (Figure 3B). With the microarray, we found that 
RASSF1A and YAP1 expression also normalized MDM2 
mRNA levels (Table 1). Subsequently, we analyzed 
protein levels of MDM2 by western blot analyses after 
YAP1 and/or RASSF1A overexpression in TREx293 
cells and HEK293T cells (Supplementary Figure 6 and 
Figure 7). Interestingly in TREx293 cells, RASSF1A 
co-expression and YAP1 induction resulted in reduced 
MDM2 protein levels (30% reduction; Supplementary 
Figure 6E). This effect was confirmed by transient 
transfection of RASSF1A and YAP1 in HEK293T cells 
(Figure 7A–7B). Expression of RASSF1A and YAP1 
resulted in a significant downregulation of MDM2 (40% 
reduction) and a 1.4-fold increase in BAX and p53 levels 
compared to control transfection (Figure 7A and 7B).
The microarray analysis revealed additional genes 
that were upregulated by YAP1 and RASSF1A in TREx293 
cells (Table 1). Some of the identified genes, like HIF1A-
AS2 and AJUBA are related to hypoxia. The Lim domain 
protein AJUBA has been linked to the Hippo pathway [38] 
and in our study we observed its induction by RASSF1A 
and YAP1 (Figure 3A). Other genes such as ACTBL2 and 
COL12A1 are involved in the regulation of the cytoskeleton. 
CYR61 and CTGF were previously identified as YAP1 
target genes [8, 39]. Additionally, we found that RASSF1A 
and YAP1 induced the downregulation of FOS, MAP2K6, 
GDF15, FOXD3, FGF21 and other genes (Table 1).
Figure 1: YAP1 regulates the expression of tumor-associated genes. (A) Relative expression of YAP1 in TREx293 clone pool 
after 24 h induction with 2 µg/ml Doxycyclin (YAP1 ind.) compared to uninduced cells (unind. = 1). All expression data were obtained by 
qRT-PCR and normalized to GAPDH level. (B) Relative expression of ANKRD1, CTGF, RASSF1A, TP53, BAX, CDKN1A and BBC3 after 
24 h induction of YAP1 (YAP1 ind.) compared to uninduced cells (unind.). (C) Western blot analysis of YAP1 in TREx293 cells after 72 h 
transfection with GFP-empty or GFP-RASSF1A with and without induction of YAP1. p-values *p < 0.05, **p < 0.01 and ***p < 0.001.
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ANKRD1 is a tumor suppressive target gene of 
YAP1 and RASSF1A
Subsequently, we focused our experiments on 
ANKRD1, which is significantly upregulated through the 
combined expression of RASSF1A and YAP1 (Figures 2C 
and 3A and Table 1). The activation of the ANKRD1 
promoter following YAP1 and RASSF1A expression was 
confirmed by promoter assay (Figure 3C). However, when 
we utilized a RASSF1A construct that lacks the SARAH 
domain (ΔSARAH), the activation of the ANKRD1 
promoter was significantly reduced (Figure 3C).
Additionally, we performed a Crispr/Cas9 mediated 
knockdown of YAP1 in HEK293T cells and analyzed 
Figure 2: RASSF1A induces cell cycle arrest, apoptosis and ANKRD1 expression. (A) Flow cytometry analysis of YAP1 in 
TREx293 cells transfected with a GFP control or GFP-RASSF1A plasmid after 72 h treatment with Doxycycline (YAP1 ind.) or without 
(unind.). Cell cycle distribution was analyzed via flow cytometry using propidium iodid staining (n = 104 cells). (B) Nuclear morphology 
after YAP1 and RASSF1A transfection. mCherry-YAP1 and GFP-RASSF1A and/or control plasmid were transfected in HEK293T cells; 
nuclei of transfected cells were analyzed by fluorescence microscopy after 72 h (n = 200 each). (C) Quantitative analysis of ANKRD1 
expression level in HEK293T cells transfected with control, YAP1 and/or RASSF1A after 72 h. All expression data obtained by qRT-PCR 
were normalized to GAPDH and Ctrl was set 1. (D) Quantitative analysis of ANKRD1 expression level in HeLa cells transfected with 
control, YAP1 and/or RASSF1A after 72 h. p-values *p < 0.05, **p < 0.01 and ***p < 0.001 (t-test).
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the expression levels of YAP1 and ANKRD1 in several 
clones (Figure 4). In seven clones, a considerable 
knockdown of YAP1 compared to the control clone 
was detected (Figure 4A). Downregulation of YAP1 
significantly correlated with decreased ANKRD1 mRNA 
levels (p = 0.05). Subsequently, we utilized four YAP1 
knockdown clones to analyze the effect of RASSF1A 
transfection on ANKRD1 levels (Figure 4B and 
Supplementary Figure 7). In HEK293T control cells 
significantly increased ANKRD1 levels were found 
after RASSF1A and/or YAP1 expression (Figure 4B). 
However, after YAP1 knockdown the induced expression 
of ANKRD1 was absent (Figure 4B). This indicates that 
RASSF1A regulates ANKRD1 via YAP1 signaling.
Next, the expression of ANKRD1 in normal tissues 
from heart, breast, liver and lung was analyzed (Figure 5). 
Although, in breast tissue ANKRD1 was absent, a clear 
expression was found in heart, liver and lung tissues 
(Figure 5A). We also analyzed the expression of ANKRD1 
and YAP1 in different human cancer cell lines, including 
lung cancer (H322, A549 and A427), prostate cancer 
(LNCaP and PC-3), breast cancer (MCF7) and skin cancer 
(MeWo and Sk-Mel-28). YAP1 expression was observed 
in all analyzed samples (Figure 5B). However, ANKRD1 
expression was very low in several cancer cell lines (e.g. 
LNCaP, MCF7 and MeWo; Figure 5B and 5D). Thus 
we investigated the promoter methylation of ANKRD1 
in these cancer cells by combined bisulfite restriction 
analysis (Figure 5C). In HEK293T, in which ANKRD1 
is expressed, the analyzed CpG site was unmethylated 
(Figure 5C). In LNCaP, MeWo, A427 and MCF7 cells, 
the CpG site was methylated. We therefore analyzed the 
Figure 3: RASSF1A regulates the expression of YAP1 target genes. (A) Expression of CTGF, ANKRD1, AJUBA, TP53, BAX, 
CDKN1A and MDM2 was analyzed in TREx293 cells after 72 h transfection with GFP-empty or GFP-RASSF1A and without (unind.) or 
with YAP1 induction (YAP1 ind.). RNA levels in control cells (GFP/unind.) were set 1. (B) Firefly luciferase activity at the BAX, CDKN1A 
and synthetic p53 target site promoters with and without overexpression of RASSF1A and YAP1 induction (YAP1 ind.) or uninduced 
TREx293 cells (Ctrl/unind. = 1). All data were normalized to renilla luciferase activity. (C) Luciferase activity of ANKRD1 promoter 
after RASSF1A, RASSF1A-ΔSARAH (deletion of SARAH domain) or control (Ctrl) transfection with and without induction of YAP1 in 
TREx293 cells. Promoter activity was normalized to firefly luciferase activity and control (Ctrl/unind = 1). p-values *p < 0.05, **p < 0.01 
and ***p < 0.001.
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effect of a DNA methylation inhibitor (Aza: 5-Aza-2′-
deoxycytidine) on the expression of ANKRD1 in these 
cell lines (Figure 5D). Expression of ANKRD1 was 
downregulated in LNCaP, MeWo, A427 and MCF7, but 
after treatment with 5 and 10 µM Aza, we observed a 
re-expression of ANKRD1 (Figure 5D). These findings 
indicate that ANKRD1 is epigenetically silenced in these 
cancer cells. In LNCaP cells that harbor a methylated 
ANKRD1 promoter, the induction of ANKRD1 by YAP1 
was significantly reduced compared to HEK293T cells 
(Supplementary Figure 8).
Subsequently, we investigated the effect of ectopic 
ANKRD1 expression on colony formation in LNCaP, 
A427 and HEK293T cells (Figure 5E). ANKRD1 
expression significantly reduced the number of colonies 
in LNCaP (42%; p < 0.001), in A427 (80%; p < 0.001) 
and in HEK293T (87%; p < 0.0001), compared to control 
transfected cells (Figure 5F). Consequently, we generated 
TREx293 cells with a doxycycline-dependent inducible 
ANKRD1 expression. The induction of ANKRD1 resulted 
in a significant upregulation of TP53 (1.4-fold), BAX 
(1.3-fold) and CDKN1A (1.3-fold; Figure 6A). We also 
analyzed the effect of ANKRD1 expression on TP53, BAX 
and CDKN1A levels in HEK293T cells (Supplementary 
Figure 9A). We observed that expression of ANKRD1 
caused a significant activation of TP53 (1.5-fold), BAX 
(1.2-fold) and CDKN1A (1.2-fold) (Supplementary 
Figure 9A). A significant increased expression of 
TP53 (1.2- to 1.9-fold) was also observed in LNCaP, 
MeWo, A549 and A427 after ANKRD1 overexpression 
(Supplementary Figure 9B). Moreover, we observed by 
promoter assays that ANKRD1 significantly activated 
the BAX promoter (Figure 6B). Next, we analyzed the 
effect of RNAi-mediated downregulation of ANKRD1 on 
the expression of TP53, BAX and CDKN1A (Figure 6C). 
We transfected HEK293T cells with siRNA against 
ANKRD1 and observed a reduction of 87% in ANKRD1 
mRNA levels compared to control siRNA (Figure 6C). 
Additionally, we observed that mRNA levels of TP53 
(28% reduction), BAX (24% reduction) and CDKN1A 
(44% reduction) were also downregulated after RNAi 
mediated-knock down of ANKRD1 (Figure 6C).
Table 1: RASSF1A and YAP1 regulated target genes
Gene GFP/unind. GFP/YAP1 ind. RASSF1A/unind. RASSF1A/YAP1 ind.
HIF1A-AS2 1,00 7,70 1,16 10,90 Top 10 up-regulated genes
ACTBL2 1,00 2,72 1,16 4,85
COL12A1 1,00 4,60 1,11 4,41
CTGF 1,00 2,26 1,34 3,97
MT-TW 1,00 2,90 2,58 3,64
ANKRD1 1,00 2,88 1,24 3,40
CYR61 1,00 2,66 1,43 3,26
CPA4 1,00 2,74 1,24 3,22
AJUBA 1,00 2,25 1,20 2,77
SPANXC 1,00 1,69 1,55 2,67
CDKN1A 1,00 0,64 0,84 0,91
TP53 1,00 0,79 0,95 0,95
BAX 1,00 0,63 0,83 1,00
MDM2 1,00 0,98 1,30 0,98
FOS 1,00 0,92 0,97 0,73 Top 10 dow
n-regulated genes
MAP2K6 1,00 1,15 0,91 0,59
PINK1
TP53I13
1,00 0,86 0,71 0,56
1,00 0,81 0,84 0,51
GDF15 1,00 0,60 0,72 0,46
FOXD3 1,00 0,74 0,48 0,46
FGF21 1,00 0,59 0,46 0,45
ANAPC1P1 1,00 0,65 0,54 0,45
GH1 1,00 0,57 0,65 0,41
MAP3K8 1,00 0,40 0,89 0,39
Expression of top 10 up- and downregulated genes and selected target genes (bold) after YAP1 induction (+Doxycyclin) and 
RASSF1A transfection in TREx293 cells. Levels were normalized to GFP/-Dox (unind. = 1) and microarray controls.
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The tumor suppressive function of ANKRD1 
depends on p53
To further characterize the function of ANKRD1, 
we analyzed the protein levels of MDM2, p53 and BAX 
after ectopic ANKRD1 expression in HEK293T cells 
(Figure 7A and 7B). Here, we observed that ANKRD1 
expression increased protein levels of p53 (1.3-fold) 
and BAX (1.8-fold). However, MDM2 was significantly 
downregulated (40% reduction) to similar levels as 
detected after RASSF1A and YAP1 co-transfection 
(Figure 7A and 7B). Previously, it has been reported that 
ANKRD1 interacts with p53 [20]. We confirmed this 
interaction by co-immunoprecipitation of Flag-ANKRD1 
with endogenous p53 (Figure 7C). Interestingly, we 
also found the co-immunoprecipitation of MDM2 with 
ANKRD1 (Figure 7C). Interaction of ANKRD1 with 
MDM2 and p53 was verified using GFP-tagged ANKRD1 
(Supplementary Figure 10).
To further dissect the tumor suppressive function 
of ANKRD1 in the p53 pathway, we utilized the colon 
cancer cell line HCT116 that harbors a homozygote 
deletion of the TP53 locus (HCT116 TP53−/−) and the 
corresponding HCT116 wild type (HCT116 TP53+/+) 
[40]. In HCT116 TP53−/− cells no p53 protein could be 
detected (Figure 7D). We investigated the effect of ectopic 
Figure 4: YAP1 knockdown results in reduced ANKRD1 levels. (A) For the Crispr-Cas9 mediated YAP1 knockdown, HEK293T 
cells were transiently transfected with 4 µg YAP1-pSpCas9(BB)-2A-Puro plasmid. After three weeks of 1 µg/ml puromycin selection, 
seven individual clones were expanded and RNA was isolated. YAP1 and ANKRD1 expression was analyzed by qRT-PCR and levels were 
normalized to GAPDH and a control clone (= 1). (B) Four clones with YAP1 knockdown (> 85% reduction) were transfected with GFP 
and GFP-RASSF1A. As a control HEK293T cells were also transfected with YAP1 and/or RASSF1A. After 72 h RNA was isolated and 
ANKRD1 expression was analyzed by qRT-PCR. Levels were normalized to GAPDH and plotted relative to HEK293T GFP control (= 1). 
p-values for HEK293T cells: **p < 0.01 and ***p < 0.001.
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ANKRD1 expression on p53 level and colony formation 
(Figure 7). In p53 wild type HCT116 cells, we observed a 
significant 1.8-fold induction of p53 by ANKRD1 (Figure 
7D and 7E). Increase levels of p53 were also found after 
RASSF1A and YAP1 co-transfection (Supplementary 
Figure 11). Additionally, we revealed a reduction of 
MDM2 levels after overexpression of ANKRD1 or co-
transfection of RASSF1A and YAP1 in HCT116, which 
confirmed our previous data in HEK293T (Supplementary 
Figure 11 and Figure 7). Co-transfection of RASSF1A and 
YAP1 also resulted in an induction of ANKRD1 expression 
in HCT116 (Supplementary Figure 8). Subsequently, we 
analyzed the effect of ANKRD1 on colony formation in 
wild type and p53-depleted HCT116 cells (Figure 7F). In 
HCT116 TP53+/+ cells, ANKRD1 drastically reduced the 
colony formation compared to control transfected cells. 
Figure 5: Epigenetic inactivation of ANKRD1 in human cancer. (A) Expression of ANKRD1 was analyzed in normal heart, breast, 
liver and lung tissues by qRT-PCR. Expression was normalized to GAPDH and ANKRD1 expression in heart was set 1. (B) Expression of 
ANKRD1 and YAP1 in cancer cell lines. ANKRD1 and YAP1 expression was analyzed in the indicated cell lines by qRT-PCR and normalized 
to GAPDH expression and levels in HEK293T were set 1. (C) DNA methylation analysis of the ANKRD1 promoter region. The methylation 
was analyzed in LNCaP, MeWo, A427, MCF7 and HEK293T cells by combined bisulfite restriction analysis. Combined bisulfite restriction 
analysis covers one third of all CpGs in the analyzed region. PCR products were digested with TaqI (+) and mock digest (−). Length of 
PCR product: 139 bp and restriction products: 92 bp (arrow) and 47 bp. ivm: in vitro methylated DNA from HeLa cells; m: methylated u: 
unmethylated. (D) Re-expression of ANKRD1. The expression of ANKRD1 and GAPDH in the indicated cancer cells was analyzed after 
5 days of 5 Aza-2′-deoxycytidine treatment (0, 5 and 10 µM Aza) via semi-quantitative RT-PCR. (E) Ectopic expression of ANKRD1 
reduced colony formation in cancer cells. Flag-empty vector (Ctrl) or Flag-ANKRD1/pCDNA4TO were transfected in LNCaP, A427 and 
HEK293T cells. After three weeks selection with G418 (LNCaP and A427) or Zeocin (HEK293T), colonies were stained and quantified. 
(F) Reduced colony count through ANKRD1. The colonies were counted and plotted relative to Ctrl (100%); ***p < 0.001.
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In contrast, in HCT116 TP53−/− cells this reduction in 
colonies was not found (Figure 7F). This data suggests 
that the tumor suppressive effect of ANKRD1 depends on 
the presence of p53.
DISCUSSION
Cellular homeostasis is the precise balance 
between cell growth and death; disturbing this fine-
tuning ultimately results in cancer. The Hippo pathway 
plays a crucial role in the regulation of organ size and 
carcinogenesis [41, 42]. The inactivation or activation 
of key regulators leads to an imbalance in this pathway, 
which may alter the pro-apoptotic effect of the Hippo 
pathway by switching it into the oncogenic function [43]. 
The downstream transcriptional activator of the Hippo 
pathway is YAP1, which is described as an oncogenic 
factor often activated in cancer [17, 44, 45]. In this study, 
we observed that the induction of YAP1 moderately 
reduced the expression of tumor suppressor genes 
including TP53, BAX, CDKN1A and RASSF1A (Figure 1 
and Figure 3). Moreover, the overexpression of YAP1 
elevates the mRNA level of the connective tissue growth 
factor CTGF and MDM2 and induces S-phase (Figure 2 
and Figure 3). The oncogenic function of YAP1 is 
mediated through the TEAD complex and the activation of 
proliferative genes like CTGF and cyclin D1 [8, 17]. It has 
been reported that p53 directly regulates the expression 
of RASSF1A [26, 28] and that the loss of RASSF1A 
promotes the formation of an oncogenic YAP1-TEAD 
complex [46]. In this context, it is important to note that 
TREx293, which are derived from HEK293 cells exhibit 
a RASSF1A promoter hypermethylation (Supplementary 
Figure 5). The scaffold protein RASSF1A is an important 
tumor suppressive regulator of the Hippo kinases MST1/
MST2 and the large tumor suppressor kinases LATS1/
LATS2 [3, 5, 33]. RASSF1A interacts with MST1/
MST2 through their common SARAH domain [2, 47]. 
RASSF1A is one of the most frequent epigenetically 
inactivated genes in different types of human cancer and 
acts as a prominent tumor suppressor [31, 34, 37]. We 
analyzed the promoter methylation of members of the 
Hippo pathway in hepatocellular cancer and observed 
tumor-specific hypermethylation of RASSF1A, although 
YAP1 was unmethylated (Supplementary Figure 4). It 
has been shown that RASSF1A regulates YAP1 through 
the Hippo pathway [5, 48]. Here we revealed that re-
expression of RASSF1A promotes its tumor suppressive 
function through the activation of pro-apoptotic and anti-
proliferative YAP1 target genes (e.g. BAX and CDNK1A) 
in TREx293 cells (Figure 3). Matallanas et al. (2007) 
have shown that RASSF1A elicits apoptosis through the 
Hippo pathway by activating the transcription of pro-
apoptotic genes via YAP1 and p73 [5]. We also observed 
that RASSF1A counteracts the oncogenic properties of 
YAP1 by preventing the YAP1-induced downregulation 
of BAX, CDKN1A and TP53 (Figure 3 and Table 1). 
Moreover, RASSF1A induces apoptosis and accumulates 
the cells in G0/G1 phase (Figure 2). In A549 lung cancer 
cells, we observed the upregulation of CDKN1A and 
BAX after re-expression of RASSF1A confirming its 
apoptotic functions [49]. In this study interestingly, we 
found reduced protein levels of MDM2 after RASSF1A 
and YAP1 co-expression (Figure 7). However, mRNA 
levels of MDM2 were not reduced compared to uninduced 
cells (Figure 3 and Table 1). MDM2 acts as E3 ubiquitin 
ligase that target p53 for proteasomal degradation [22]. 
It has been reported that RASSF1A negatively regulates 
MDM2 by disrupting the MDM2-DAXX-HAUSP 
complex and inducing the self-ubiquitination of MDM2 
[50]. p53 regulates the transcription of MDM2 by a 
positive feedback loop [23, 25]. We also observed that 
Figure 6: ANKRD1 regulates the expression of tumor suppressor genes. (A) Relative expression of TP53, BAX and CDKN1A 
in ANKRD1 inducible TREx293 cells with and without ANKRD1 induction by Dox (2 µg/ml), normalized to GAPDH and uninduced 
TREx293 cells (unind. = 1). (B) ANKRD1 activates the BAX promoter. Relative luciferase activity of the BAX promoter after 24 h 
overexpression of Flag-empty vector (Ctrl = 1) or Flag-ANKRD1 was analyzed in HEK293T cells. (C) Relative expression of tumor 
suppressor genes after ANKRD1 knockdown by RNAi. Expression of ANKRD1, TP53, BAX and CDKN1A in HEK293T cells treated with 
siRNA against ANKRD1 (siANKRD1). RNA levels were analyzed by qRT-PCR and normalized to GAPDH and control siRNA (siCtrl = 1). 
p-values *p < 0.05, ** p < 0.01 and ***p < 0.001.
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Figure 7: Tumor suppressive function of ANKRD1. (A) Representative Western blot of overexpression/co-transfection of Flag-
empty, Flag-RASSF1A, Flag-YAP1, Flag-ANKRD1 after 72 h in HEK293T cells. (B) Quantification of protein levels of MDM2, p53 and 
BAX from five western blots of biological replicates with overexpression and co-transfection of Flag-empty (Ctrl), Flag-RASSF1A, Flag-
YAP1, Flag-ANKRD1 in HEK293T cells after 72 h transfection. Data were quantified and normalized to GAPDH and control lysates via 
ImageJ (Ctrl = 1). (C) Co-immunoprecipitation of MDM2 and p53 with Flag-ANKRD1. Flag-empty and Flag-ANKRD1 were transfected 
in HEK293T cells. After 72 h protein lysates were extracted and analyzed by Western-blot (input) with indicated antibodies (AB). Flag-
tagged ANKRD1 was precipitated with anti Flag beads and the co-precipitation of MDM2 and p53 was analyzed by western blot (IP: Flag). 
(D) Representative Western blot of overexpression/co-transfection of GFP-empty, GFP-ANKRD1 after 72 h in HCT116 TP53+/+ and 
HCT116 TP53−/− cells. (E) Quantification of protein levels of p53 protein level from three western blots of biological replicates with co-
transfection of GFP-empty (Ctrl) and GFP-ANKRD1 in HCT116 TP53+/+. Data were quantified and normalized to GAPDH and control 
lysates via ImageJ (Ctrl = 1). (F) Ectopic expression of ANKRD1 reduced colony formation in HCT116 TP53 wildtyp colon cancer cells. 
Flag-empty vector (Ctrl) or Flag-ANKRD1 were transfected in HCT116 TP53+/+ and HCT116 TP53−/− cells. After two weeks of selection 
with G418, colonies were stained by Giemsa. p-values *p < 0.05, **p < 0.01 and ***p < 0.001. 
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overexpression of the RASSF1A and YAP1 or their target 
gene ANKRD1 resulted in MDM2 degradation (Figure 7 
and Supplementary Figure 11). Thus it will be interesting 
to analyze ANKRD1-induded degradation of MDM2 
depends on p53.
YAP1, the main downstream regulator of the Hippo 
pathway, is highly expressed in cancer cells and involved 
in cell proliferation and tumorigenesis [16, 29, 51, 52]. 
Taking these findings into account, we observed that YAP1 
induces the expression of CTGF (Figures 1 and 3). This 
growth inducing factor is a mitogen and was previously 
associated with the oncogenic properties of YAP1 [8]. 
Moreover, it is interesting to note that the co-expression of 
RASSF1A and YAP1 repressed the expression of several 
growth-associated genes including the transcription factors 
FOS and FOXD3, the mitogen-activated protein kinases 
MAP2K6 and MAP3K8 and the growth factors FGF21, 
GH1 and GDF15 (Table 1). It has been reported that 
K-Ras and YAP1 converge on the transcription regulator 
FOS and activate a transcriptional pathway, which is 
involved in the regulation of the epithelial-mesenchymal 
transition [53]. Additional targets of YAP1 signaling, 
including CYR61 and AJUBA (Table 1 and Figure 3), have 
been described previously [38, 39, 54, 55]. Concerning 
AJUBA, it has been reported that it suppresses the 
proliferation of malignant mesothelioma via the Hippo 
pathway [56]. Interestingly, we observed that RASSF1A 
together with YAP1 induces the expression of AJUBA 
(Figure 3) and other YAP1 targets which have not been 
described so far (e.g. HIF1A-antisense 2, ACTBL2, CPA4 
and COL12A1; see Table 1). The precise tumor-related 
function of some YAP1 targets is still under investigation 
and may depend on expression levels, cell origin and/or 
the genetic and epigenetic background. 
A YAP1 target gene that displays a tumor 
suppressive effect is ANKRD1 (Figure 5 and Figure 
7). In this study, we demonstrated that ANKRD1 
level is significantly increased after re-expression of 
RASSF1A in HEK293T and TREx293 that harbor 
a methylated RASSF1A promoter (Figure 2 and 
Supplementary Figure 6). However, in HeLa cells that 
express endogenous RASSF1A [34], RASSF1A and YAP1 
overexpression had no effect on the expression level of 
ANKRD1 (Figure 2). Consequently, we observed that after 
YAP1 knockdown in HEK293T cells, the overexpression 
of RASSF1A did not induce the expression of ANKRD1 
(Figure 4). Knockdown of YAP1 significantly correlated 
with the downregulation of ANKRD1 (Figure 4). 
Previously, the YAP1-dependent regulation of ANKRD1 
had been described [18, 57]. Since knockdown of YAP1 
abolished the additional induction of ANRKD1 through 
RASSF1A, we concluded that RASSF1A regulates 
ANKRD1 through YAP1-signaling (Figure 4B). 
Moreover, the lack of the SARAH domain in RASSF1A 
exhibited a significant reduction in activation of the 
ANKRD1 promoter (Figure 3). This indicates that the 
MST1/MST2 interaction domain of RASSF1A mediates 
the regulation of ANKRD1 through the Hippo-
pathway. 
Interestingly, we found that ANKRD1 is epigenetically 
inactivated in several cancer cells including lung and prostate 
cancer (Figure 5 and Supplementary Figure 8). We revealed 
that ANKRD1 is expressed in heart, liver and lung tissue but 
is silenced in breast (Figure 5). Moreover, overexpression 
of ANKRD1 moderately induced TP53, BAX and CDKN1A 
expression (Figure 6). Consequently, siRNA mediated 
knock-down of ANKRD1 resulted in the downregulation 
of these genes (Figure 6). To date, it has been reported that 
Ankrd1 works as a co-activator of p53 [20] and contributes 
to apoptosis by mitochondrial translocation of Bax and 
p53 phosphorylation [21]. In our study, we observed that 
ANKRD1 binds p53 and MDM2 and the expression of 
ANKRD1 reduced MDM2 protein levels leading to the 
stabilization of p53 and the increase of BAX (Figure 7). Our 
results suggest that ANKRD1 may act as a tumor suppressive 
target of the Hippo signaling pathway.
It has been suggested that ANKRD1 may function 
as a transcriptional co-regulator of TP53 and reduces 
colony formation in hepatoma cells [20, 58]. Here we 
show that ectopic expression of ANKRD1 reduces colony 
formation in prostate, lung and HCT116 colon cancer cells 
(Figure 5F and 7F). Interestingly in HCT116 TP53−/−  cells 
that lack p53 protein, this reduction in colony formation 
was abolished (Figure 7F). This data indicates that the 
tumor suppressive effect of ANKRD1 depends on the 
presence of p53. Moreover, we show that ANKRD1 
interacts with p53 and MDM2 (Figure 5 and Figure 7). 
Thus it will be interesting to dissect the ANKRD1/p53/
MDM2 interaction and the induction of p53 by ANKRD1 
in further detail. 
In summary, we observed that RASSF1A promotes its 
tumor suppressive effect through activation of pro-apoptotic 
and anti-proliferative YAP1 target genes. Moreover, 
RASSF1A induces cell cycle arrest in G0/G1-phase and 
apoptosis. This suggests that the oncogenic potential of YAP1 
may arise through the epigenetic silencing of RASSF1A 
and the deregulation of YAP1 in cancer. A RASSF1A and 
YAP1 target gene that displays tumor suppressive effects 
is ANKRD1. Since we observed epigenetic silencing of 
ANKRD1, this inactivation may contribute to the oncogenic 
effect of the deregulated YAP1-signaling in cancer. We also 
showed that ANKRD1 expression led to a downregulation 
of MDM2 and induced p53 levels. Moreover, our data show 
that the tumor suppressive function of ANKRD1 depends on 
the presence of p53. 
MATERIALS AND METHODS
Cell lines and transfections and primary tissues
TREx293 cells, that stably express the Tet repressor 
(Thermo Fisher Scientific), were transfected with the 
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expression vector pcDNA4TO-YAP1 and selected with 
Zeocin (Invitrogen). The cell lines TREx293, HEK293T, 
LNCaP, A427, HeLa and A549 were cultivated in DMEM or 
RPMI with 10% FCS at 37°C under 5% CO2 concentration. 
Colon cancer cell lines HCT116 p53+/+ and HCT116 
p53−/− were obtained from Thorsten Stiewe  (University 
Marburg, Germany) and cultivated in DMEM [40]. The 
cells were transfected at a confluency of 60–80% in serum 
free media (GIBCO) with 4 or 10 µg DNA (3.5 cm, 10 
cm plates respectively). HEK293T and TREx293 cells 
were transfected using PEI. LNCaP were transfected with 
Lipofectamin (Invitrogen). A549 were transfected using 
Turbofect (Thermo Fisher Scientific). A427 and HCT116 
cells were transfected using X-tremGENE HP (Roche). 
HeLa were transfected using JetPEI (Polyplus) according 
to the manufacturer’s instructions. For the colony formation 
assay, the selection was performed using G418 (Biochrom) 
or Zeocin (Invitrogen) and colonies were stained with 
Giemsa (Fluka). Primary human hepatocellular carcinomas 
and matching normal tissue samples were obtained from 
patients of the University of Halle-Wittenberg and were 
previously described [59]. The local committee of medical 
ethics approved the use and all patients gave their consent. 
ANKRD1 knockdown
ANKRD1 knockdown was performed with small 
interfering RNA (Dharmacon). HEK293T cells were 
transiently transfected with either 50 pmol of a non-targeting 
siRNA control pool (UGGUUUACAUGUCGACUAA; 
UGGUUUACAUGUUGUGUGA; UGGUUUACAUGUU 
UUCUGA; UGGUUUACAUGUUUUCCUA) or with 50 
pmol of the siRNA for ANKRD1 (CUACAAGACCUCUCGC 
AUA; GAACCAAAGCAAUAUUCGA; CGAAUUCCGUGA 
UAUGCUU; GCUAUAAGAUGAUCCGACU) using the 
Lipofectamine® RNAiMAX (Invitrogen). The cells were 
harvested after 4d for RNA isolation and expression 
analysis. 
YAP1 knockdown by Crispr-Cas9
Two guide oligos for YAP1 genomic 
knockout were generated using the protocol by 
Ran et al. and the online tool http://tools.genome-
engineering.org. Sequences for guide oligo 1: upper 
CACCGCATCAGATCGTGCACGTCCG and lower 
AAACCGGACGTGCACGATCTGATGC and guide oligo 
2 upper CACCGCAGCAGCCGCCGCCTCAAC and 
lower AAACGTTGAGGCGGCGGCTGCTGC. YAP1 
guide oligos were cloned into pSpCas9(BB)-2A-Puro via 
Bbs1 sites. Expression of Cas9 was verified by western 
blotting through its Flag-Tag. 
For the Crispr-Cas9 mediated YAP1 knockdown, 
HEK293T cells were transiently transfected with 
4 µg YAP1-pSpCas9(BB)-2A-Puro plasmid. The 
transfected cells were further selected with Puromycin 
(PAA laboratories) in a final concentration of 1 µg/ml. 
After three weeks, individual clones were isolated and 
expanded. The clones with a reduced YAP1 expression 
(85% reduction) were transfected using PEI with GFP and 
GFP-RASSF1A for further characterization by qRT-PCR.
Constructs
Indicated full length cDNAs and promoters were 
used in the representative vectors: pEGFP-C2; pEGFP-
RASSF1A; pEGFP-ANKRD1; pCMV-Flag; pCMV-Flag-
RASSF1A; pCMV-Flag-YAP1; pCMV-Flag-ANKRD1; 
pcDNA4TO; pcDNA4TO-YAP1; pcDNA4TO-ANKRD1; 
pRL-Null; pRL-ANKRD1; pGL2-basic; pGL-p21; 
pGL-BAX; pGL-MDM2; pGL-p53. The correctness 
of all constructs was confirmed through conventional 
sequencing.
RNA expression analysis
RNA was isolated with Isol-RNA Lysis Reagent (5 
Prime). 2 µg of RNA was digested with DNase I (Thermo 
Fisher Scientific) and reversely transcribed to cDNA 
with the M-MLV Reverse Transcriptase (Promega) for 
further analysis. The primers are listed in Supplementary 
Table 1. The qPCR data were obtained with SYBR- Select 
(Thermo Fisher Scientific) and measured in triplicates in 
Rotor Gene from Corbett Research. The samples were 
normalized to GAPDH and are displayed as ratio of the 
respective control sample. 
Generation of YAP1 and ANKRD1 stable cell 
lines
We created the stable cell lines in the TREx293 
Tet-On inducible system (Clontech). cDNA of YAP1 
or ANKRD1 were cloned into pcDNA4TO Myc vector 
and transfected into the TREx293 cells. The cells were 
cultivated in DMEM with 10% tetracycline free serum 
(Biochrom) and 1% penicillin and streptomycin (GIBCO) 
under the same conditions as described above. The 
selection of the clones was performed using blasticidin 
(5 µg/ml, Roth) and zeocin (500 µg/ml, Invitrogen). The 
induction of YAP1 or ANKRD1 was performed using 
doxycycline (2 µg/ml, Invitrogen).
Methylation analysis
The methylation of ANKRD1, RASSF1A, MST1, 
MST2, WW45, LATS1, LATS2, YAP1 and KIBRA 
promoters were analyzed via combined bisulfite restriction 
analysis (CoBRA) as described previously [34, 60]. 
Bisulfite specific primers are listed in Supplementary 
Table 1. 2 µg DNA were bisulfite treated to convert 
unmethylated cytosine into uracil. The region of interest 
from DNA of each cell line was amplified by PCR using 
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the specific primers for bisulfite DNA (Supplementary 
Table 1). The obtained PCR products were further digested 
with TaqI (Thermo Fisher Scientific) for 1 h at 65°C. The 
digested products were resolved on a 2% agarose gel. 
Western blot, antibodies and immuno-
precipitation
The cell lysates were loaded on 10% SDS gels and 
blotted onto a PVDF membrane (Amersham). Santa Cruz 
Antibodies: anti YAP1 H-125 (1:200), anti GAPDH FL-
335 (1:2000), anti p53 Do-I (1:2000) and anti ANKRD1 
H-120 (1:200). Anti mp53 1C12 (1:1000) from Cell 
Signaling, anti MDM2 Ab-2 (1:1000) from Calbiochem. 
Anti BAX 06-499 (1:1000) from Millipore and anti GFP 
rabbit polyclonal serum (1:2000). The protein levels 
were quantified using ImageJ after subtraction of the 
background and normalized to GAPDH levels and control 
lysates. 
For the immunoprecipitation, HEK293T cells were 
transiently transfected either with 10 µg of pCMV-Flag-
ANKRD1 or pEYFP-ANKRD1 and empty vector control, 
respectively. The cell lysates were incubated overnight 
with anti-flag M2 agarose beads (Sigma) or with anti-GFP 
agarose beads (Chromotek). The beads were washed twice 
with cold TBS before denaturation. The cell lysates (input) 
and IPs were separate by SDS-PAGE. The interactions 
were further analyzed by western blotting using the 
specific antibodies. 
FACS and microarrays
Cell cycle distribution was analyzed via flow 
cytometry (BD FACSCanto) using propidium iodid 
(Sigma) and pEGFP or pEGFP-RASSF1A transfected 
TREx293 cells (−/+ doxycycline). For the microarrays, 
106 cells were sorted in BD Biosciences FACS Aria III 
flow cytometer. The purity (GFP signal) of the sorted cells 
was analyzed after sorting as shown in Supplementary 
Figure 6. RNA from the sorted cells was obtained using 
Isol-RNA Lysis Reagent (5 Prime); 250 ng RNA was 
employed for the expression analysis by Affymetrix arrays: 
HuGene version 2.0 (Affymetrix). Microarray data are 
available in the ArrayExpress database (www.ebi.ac.uk/
arrayexpress) under accession number E-MTAB-4781.
Promoter assays
The ANKRD1 promoter (600 bp) was cloned into 
pRL-null vector. The promoters of a synthetic TP53 target 
site (250 bp with 13 p53 binding sites: GGACTTGCCT), 
p21 and BAX cloned into pGL-vectors were obtained 
from Lienhard Schmitz (Justus-Liebig-University, 
Germany). The transfection efficiency was controlled 
using the corresponding empty control vector (300 ng 
firely or renilla luciferase controls, respectively). The 
measurements were performed using the Dual-Luciferase 
Reporter Assay System (Promega) and the microplatte 
illuminometer ORION L (Berthold). The obtained data 
were normalized to the corresponding control vectors.
Fluorescence microscopy 
HEK293T cells were seeded onto cover slips in 
6-well plates and transfected with pEGFP or pEGFP-
RASSF1A together with mCherry or mCherry-YAP1. 
After 72 h, cells were washed twice with PBS (Sigma) 
and fixed by 3.7% formaldehyde (Roth). After washing 
with PBS, the cells were permeabilized with 0.2% TritonX 
(Roth). DAPI (1 µg/ml, Serva Electrophoresis) was used 
for nuclear staining. The nucleus morphology of n = 200 
cells were analyzed using the 63× zoom lens of Axio 
Observer.Z1 microscope (Zeiss) with a camara Orca-ER 
(Hamamatsu) and Volocity software. 
Statistical analysis
Statistical and correlations analyses were performed 
using R version 3.1.3 (R Foundation). The data are presented 
as the means of biological triplicates ± S.D. The p-values 
were quantified by Student’s unpaired t-test or by Chi square 
test for the FACS data. The differences are considered 
significant if: *p < 0.05; **p < 0.01; ***p < 0.001.
Abbreviations
YAP1 (Yes-Associated Protein 1); ANKRD1 
(Ankyrin Repeat Domain 1/CARP); RASSF1A (Ras 
Association Domain Family 1A); TP53 (Tumor 
Suppressor p53); CDKN1A (Cyclin-dependent Kinase 
Inhibitor 1A/p21); BAX (BCL2-associated X protein); 
MDM2 (human homologue of mouse double minute 2), 
BBC3 (BCL2 binding component 3/PUMA). 
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